Show simple item record

dc.contributor.authorChiappini, Stephania
dc.contributor.authorClaridge, Hugh
dc.contributor.authorCorkery, John
dc.contributor.authorGoodair, Christine
dc.contributor.authorLoi, Barbara
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2016-03-30T14:10:51Z
dc.date.available2016-03-30T14:10:51Z
dc.date.issued2015-07-28
dc.identifier.citationChiappini , S , Claridge , H , Corkery , J , Goodair , C , Loi , B & Schifano , F 2015 , ' Methoxetamine-related deaths in the UK : an overview ' , Human Psychopharmacology: Clinical and Experimental , vol. 30 , no. 4 , pp. 244-248 . https://doi.org/10.1002/hup.2422
dc.identifier.issn0885-6222
dc.identifier.otherPURE: 7205095
dc.identifier.otherPURE UUID: 91b433f0-ca36-484f-bd4e-ce897b87db94
dc.identifier.otherScopus: 84938061631
dc.identifier.urihttp://hdl.handle.net/2299/16849
dc.description.abstractObjective: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011–2013, presented at the Second International Conference on Novel Psychoactive Substances. Methods: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related deaths from Coroners in the UK and Islands (Isle of Man, Jersey, Guernsey) and other data suppliers. Results: Eight cases, received by 3 September 2013, in which MXE was found at post-mortem and/or directly implicated in the death and/or mentioned in the Coroner's verdict are described. The median age at death was 27 years, with the majority of White ethnicity (6/8) and male (7/8). MXE was used together with other substances in 7/8 cases. MXE was found at post-mortem in all cases, directly implicated in the deaths of four and likely to have had an influence in two. Conclusions: More research needs to be conducted into its health effects and toxicity potential. Health care professionals should be made aware of the potential health harms of MXE, in order to develop early intervention measures and minimise the number of MXE-related poisonings and fatalities.en
dc.format.extent5
dc.language.isoeng
dc.relation.ispartofHuman Psychopharmacology: Clinical and Experimental
dc.subjectmethoxetamine
dc.subjectMXE
dc.subjectnovel psychoactive substances
dc.subjectNPS
dc.subjectlegal high
dc.subjectdesigner drugs
dc.titleMethoxetamine-related deaths in the UK : an overviewen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionPrescription and Illicit Drug Misuse
dc.contributor.institutionPublic Health
dc.contributor.institutionPatient and Medicines Safety
dc.description.statusPeer reviewed
dc.date.embargoedUntil2016-07-28
rioxxterms.versionAM
rioxxterms.versionofrecordhttps://doi.org/10.1002/hup.2422
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record